- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Alectinib
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 2,165
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Bladder Cancer, Kidney Cancer, Lung Cancer
- Interventions
- tucotuzumab celmoleukin
- Biological
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 2
- States / cities
- Washington D.C., District of Columbia • New York, New York
- Conditions
- Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult, Metastatic Tumor, Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Endometrial Neoplasms, Endometrial Diseases, Metastatic Endometrial Cancer, Triple Negative Breast Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Ovarian Carcinoma, Gastric Cancer, Advanced Gastric Carcinoma, Metastatic Gastric Cancer, Metastatic Gastric Carcinoma, Small Cell Lung Cancer, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms, Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma, CCNE1 Amplification, Hormone Receptor Negative Breast Carcinoma, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Progesterone-receptor-positive Breast Cancer
- Interventions
- NKT3964, Paclitaxel, Doxorubicin
- Drug
- Lead sponsor
- NiKang Therapeutics, Inc.
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Non-Small Cell Lung Cancer, Small Cell Lung Cancer
- Interventions
- Durvalumab, Cisplatin, Carboplatin, Etoposide
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Houston, Texas • Fairfax, Virginia
- Conditions
- Lung Cancer
- Interventions
- Celecoxib, ZD1839
- Drug
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC), Urothelial Carcinoma (UC), Solid Tumor, Hepatocellular Carcinoma (HCC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Head and Neck Squamous Cell Carcinoma (HNSCC), Clear Cell Renal Cell Carcinoma (ccRCC), Non-Clear Cell Renal Cell Carcinoma (nccRCC), Drug-Drug Interaction (DDI)
- Interventions
- Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone, Docetaxel, DDI Probe Cocktail
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,394 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Palo Alto, California + 38 more
- Conditions
- Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
- Interventions
- Cetuximab, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 14
- States / cities
- Little Rock, Arkansas • Long Beach, California • Boynton Beach, Florida + 11 more
- Conditions
- Lung Cancer
- Interventions
- adjuvant therapy, diagnostic thoracoscopy, therapeutic thoracoscopy, video-assisted surgery, radiation therapy
- Procedure · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2005
- U.S. locations
- 13
- States / cities
- Denver, Colorado • Des Moines, Iowa • Boston, Massachusetts + 8 more
- Conditions
- Clear Cell Renal Cell Cancer, Non-Small-Cell Lung Cancer, Triple Negative Breast Neoplasms, Squamous Cell Cancer of Head and Neck, Small Cell Lung Cancer, Gastroesophageal Cancer, Melanoma, Cervical Cancer, Advanced Solid Tumours
- Interventions
- AZD8701, Durvalumab
- Drug · Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 101 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 6
- States / cities
- Baltimore, Maryland • St Louis, Missouri • Huntersville, North Carolina + 3 more
- Conditions
- Advanced Cancer
- Interventions
- Nivolumab, Daratumumab
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more
- Conditions
- Small-Cell Lung Cancer, Neuroendocrine Carcinoma
- Interventions
- Gocatamig, Atezolizumab, Ifinatamab Deruxtecan (I-DXd)
- Biological
- Lead sponsor
- Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 11
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- ZD6474, Paclitaxel, Carboplatin
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 12
- States / cities
- Concord, California • Los Angeles, California • Chicago, Illinois + 9 more
- Conditions
- Advanced Solid Tumors, Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non Small Cell Lung Cancer, Triple Negative Breast Cancer
- Interventions
- MM-151, MM-151 + irinotecan
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 4
- States / cities
- Aurora, Colorado • Lafayette, Indiana • Buffalo, New York + 1 more
- Conditions
- Smoking Cessation
- Interventions
- Text messaging plus nicotine replacement therapy, Standard Care at Lung Cancer Screening
- Behavioral · Other
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2024
- U.S. locations
- 1
- States / cities
- Charleston, South Carolina
- Conditions
- Healthy Volunteers
- Interventions
- [14C]lorlatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor, Localized Extrahepatic Bile Duct Cancer, Localized Gallbladder Cancer, Localized Gastrointestinal Carcinoid Tumor, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Gastrointestinal Carcinoid Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Primary Peritoneal Cavity Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Adult Soft Tissue Sarcoma, Recurrent Colon Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Small Intestine Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Small Intestine Adenocarcinoma, Small Intestine Leiomyosarcoma, Small Intestine Lymphoma, Stage 0 Non-small Cell Lung Cancer, Stage I Adult Soft Tissue Sarcoma, Stage I Colon Cancer, Stage I Gastric Cancer, Stage I Non-small Cell Lung Cancer, Stage I Ovarian Epithelial Cancer, Stage I Ovarian Germ Cell Tumor, Stage I Pancreatic Cancer, Stage I Rectal Cancer, Stage I Uterine Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage II Colon Cancer, Stage II Gastric Cancer, Stage II Non-small Cell Lung Cancer, Stage II Ovarian Epithelial Cancer, Stage II Ovarian Germ Cell Tumor, Stage II Pancreatic Cancer, Stage II Rectal Cancer, Stage II Uterine Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Uterine Sarcoma, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Adult Soft Tissue Sarcoma, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Uterine Sarcoma, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
- Interventions
- EF5, motexafin lutetium, pharmacological study
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Primary Brain Tumors, Metastatic Malignant Neoplasm to Brain
- Interventions
- 4-Demethyl-4-cholestryloxycarbonylpenclomedine
- Drug
- Lead sponsor
- DEKK-TEC, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 3
- States / cities
- New Orleans, Louisiana • Lansing, Michigan • Houston, Texas
- Conditions
- Non Small Cell Lung Cancer, Cervical Cancer, SCCHN, Pancreatic Cancer, Esophageal SCC, Metastatic Castration-resistant Prostate Cancer, Triple Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Tissue Factor-Expressing Solid Tumors
- Interventions
- XB002, Nivolumab, Bevacizumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 25 more
- Conditions
- Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer AJCC v8
- Interventions
- Berzosertib, Biospecimen Collection, Carboplatin, Computed Tomography, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Pembrolizumab
- Drug · Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 34
- States / cities
- Los Angeles, California • Newport Beach, California • Aventura, Florida + 25 more
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Colorectal Cancer
- Interventions
- LYL845
- Biological
- Lead sponsor
- Lyell Immunopharma, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 18
- States / cities
- Sacramento, California • Santa Monica, California • Stanford, California + 14 more
- Conditions
- Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
- Interventions
- Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
- Behavioral
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years to 39 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Colorectal Cancer; Lung Cancer
- Interventions
- TATE and pembrolizumab, TAS-102 pill, Regorafenib Pill
- Drug
- Lead sponsor
- Teclison Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 1
- States / cities
- Orange, California
- Conditions
- Esophagitis, Pneumonitis, Non-Small Cell Lung Carcinoma
- Interventions
- Amifostine
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 24
- States / cities
- Los Angeles, California • Sacramento, California • Torrington, Connecticut + 21 more
- Conditions
- Locally Advanced Non-Small Cell Lung Cancer, Lung Adenocarcinoma
- Interventions
- Cromolyn Sodium
- Drug
- Lead sponsor
- Carcinex Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- Denver, Colorado